By Marie Rosenthal
Seattle—A novel, investigational drug appears to be promising in rapidly suppressing HIV, according to study results announced at the 2017 Conference on Retroviruses and Opportunistic Infections.
Data from the Phase II study evaluating the efficacy, safety and tolerability of a combination of bictegravir (BIC) and emtricitabine-tenofovir alafenamide (FTC/TAF; Descovy, Gilead) versus dolutegravir (DTG; Tivicay, ViiV) and FTC/TAF in HIV patients who were treatment naive
FEBRUARY 15, 2017